Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
6.78
+0.10 (1.50%)
At close: Jan 8, 2026, 4:00 PM EST
6.77
-0.01 (-0.15%)
Pre-market: Jan 9, 2026, 7:07 AM EST
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$199,851
Profits / Employee
-$2,262,069
Market Cap
73.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KZIA News
- 1 day ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
- 18 days ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
- 4 weeks ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
- 5 weeks ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga
- 5 weeks ago - Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire
- 2 months ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire
- 3 months ago - Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - PRNewsWire